If you talk to cancer researchers about barriers to scientific progress, you’ll probably hear this statistic: Only about 8% of people with cancer actually take part in clinical trials.

This being 2019, a lot of people think the problem can be solved with mobile apps that connect patients to the trials that might be right for them. But — this being 2019 — the use of such technology raises some thorny questions about privacy, consent, and conflict of interest.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy